RxDoctor Payments Data

Garland Tang, MD

Neurology · Newark, OHNPI 1518317973

Payments from drug & device makers

$34,194in general payments, 2019–2025

Across 366 payments — averaging $93.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$29K
  • AstraZeneca$510
  • Neurocrine Biosciences, Inc.$430
  • SK Life Science, Inc.$427
  • Pfizer$420
  • Biogen$365
  • plus $3K from 38 others

What the payments were for

  • Speaking & faculty fees$27,45080%
  • Travel & lodging$2911%
  • Food & beverage$6,44719%
  • Education$60%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,194 in reported general payments places this provider in the 75th percentile of 702 neurology providers in Ohio.

See all neurology providers in Ohio

Medicare billing

Part B allowed, 2024
$51,767
Medicare patients
210
Services billed
3,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine23$632,743
IngrezzaValbenazine Tosylate14$120,324
Avonex Pen (4 Pack)Interferon Beta-1a14$112,492
QuliptaAtogepant77$94,210
UbrelvyUbrogepant54$68,443
CopaxoneGlatiramer Acetate11$62,378
XcopriCenobamate38$48,984
Nurtec OdtRimegepant Sulfate41$42,618
Aimovig AutoinjectorErenumab-Aooe26$32,753
KeppraLevetiracetam11$25,479
EliquisApixaban31$22,703
Lacosamide148$21,538
BotoxOnabotulinumtoxina13$16,244
Emgality PenGalcanezumab-Gnlm24$15,665
NayzilamMidazolam22$15,403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt, Eliquis$420$698,06495 claims
AbbVieQulipta, Ubrelvy, Botox$28,841$178,897144 claims
Neurocrine Biosciences, Inc.Ingrezza$430$120,32414 claims
Teva Pharmaceuticals USA, Inc.Copaxone$15$62,37811 claims
SK Life Science, Inc.Xcopri$427$48,98438 claims
UCB, Inc.Nayzilam$284$15,40322 claims
Eisai Inc.Fycompa$225$15,07517 claims
Upsher-smith Laboratories LLCTopiramate$17$1,408155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 702 neurology providers in Ohio.

Other neurology in Newark

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →